

substituted by 0, 1, 2, 3, 4 or 5 R^g groups or a (C₆ to C₉ heterobicycloalkyl)(C₁ to C₃ alkyl) group substituted by 0, 1, 2, 3, 4 or 5 R^g groups.

(12) ~~A method of treating or preventing a disease using~~ Use of a compound according to any one of sections 1 to 11 or pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating or preventing a disease, wherein the disease is multiple sclerosis, chronic rheumatoid arthritis, ankylosing spondylitis, systemic erythematodes, psoriasis, psoriatic arthritis, inflammatory bowel disease or asthma.

(13) A pharmaceutical composition comprising a compound according to any one of sections 1 to 11 or pharmaceutically acceptable salt thereof.

Advantageous Effects of Invention

The present invention provides a novel compound having excellent activity of inhibiting ROR γ and a method for producing the same. Further, the compound of the present invention or a pharmaceutically acceptable salt thereof is useful as a therapeutic agent or a preventive agent for autoimmune diseases, inflammatory diseases (for example, multiple sclerosis, chronic rheumatoid arthritis, ankylosing spondylitis, systemic erythematodes, psoriasis, psoriatic arthritis, inflammatory bowel disease, and asthma), metabolic diseases (especially diabetes), cancer diseases (especially malignant melanoma), or the like.

Description of Embodiments

In the following, terms used either independently or in combination in the present description will be explained. Unless particularly described, explanation of each substituent shall be common to each position. In addition, when any variable substituent (for example, R^j and the like) is present in respective arbitrary constituent elements (for example, R^f, Rⁱ, and the like), its definition is independent in the respective constituent

3, 4 or 5 R^g groups or a (C₆ to C₉ heterobicycloalkyl)(C₁ to C₃ alkyl) group substituted by 0, 1, 2, 3, 4 or 5 R^g groups.

12. ~~A method of treating or preventing a disease using~~Use of a compound according to any one of claims 1 to 11 or pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating or preventing a disease, wherein the disease is multiple sclerosis, chronic rheumatoid arthritis, ankylosing spondylitis, systemic erythematodes, psoriasis, psoriatic arthritis, inflammatory bowel disease or asthma.

13. A pharmaceutical composition comprising a compound according to any one of claims 1 to 11 or pharmaceutically acceptable salt thereof.